[{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Hypoimmunogenic Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"AgeX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"ImStem Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"IMS001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AgeX Therapeutics \/ ImStem Biotechnology","highestDevelopmentStatusID":"5","companyTruncated":"AgeX Therapeutics \/ ImStem Biotechnology"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Sernova","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Recombinant Pluripotent Stem Cell-Derived Pancreatic Islet Beta Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Sernova","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Therapeutics \/ Sernova"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Ohio State University","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AgeX-BAT1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ Ohio State University"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"University of California San Diego","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Neural Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ University of California San Diego","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Therapeutics \/ University of California San Diego"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"IMS001","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AgeX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AgeX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Lygenesis","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Termination","leadProduct":"AGEX-VASC1","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Lygenesis","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ Lygenesis"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Merger","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5\/Alpha1D\/Alpha2B\/Alpha2C receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AgeX Therapeutics \/ Serina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ Serina Therapeutics"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Merger","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5\/Alpha1D\/Alpha2B\/Alpha2C receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AgeX Therapeutics \/ Serina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ Serina Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by AgeX Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : The combined company will focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.

                          Product Name : SER-252

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          March 26, 2024

                          Lead Product(s) : POZ-apomorphine

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Serina Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          02

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : The combined company will keep Serina name and trade on the New York Stock Exchange under the ticker "SER", and focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, an...

                          Product Name : SER-252

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          August 30, 2023

                          Lead Product(s) : POZ-apomorphine

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Serina Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          03

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : The Ohio State University will use AgeX’s brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism, and...

                          Product Name : AgeX-BAT1

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 03, 2021

                          Lead Product(s) : AgeX-BAT1

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Ohio State University

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

                          Product Name : AGEX-VASC1

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 23, 2021

                          Lead Product(s) : AGEX-VASC1

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Lygenesis

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank

                          05

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : ImStem has obtained from AgeX a non-exclusive, royalty-bearing sublicense to use AgeX’s clinical-grade ESC line ESI-053 to derive ImStem’s investigational MSC product candidate IMS001 for development in COVID-19 as well as acute respiratory distress ...

                          Product Name : IMS001

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 28, 2020

                          Lead Product(s) : IMS001

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : ImStem Biotechnology

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Lead Product(s) : Recombinant Pluripotent Stem Cell-Derived Pancreatic Islet Beta Cell

                          Therapeutic Area : Endocrinology

                          Study Phase : Undisclosed

                          Sponsor : Sernova

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Details : Sernova to utilize AgeX’s UniverCyteTM gene technology to generate transplantable, universal immune-protected therapeutic cells for Sernova’s Cell PouchTM Platform.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 29, 2020

                          Lead Product(s) : Recombinant Pluripotent Stem Cell-Derived Pancreatic Islet Beta Cell

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Sponsor : Sernova

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : ImStem plans to initiate a phase 1 clinical study in patients with relapsing-remitting, secondary, and primary progressive forms of MS in 2020 in the US.

                          Product Name : IMS001

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 20, 2020

                          Lead Product(s) : IMS001

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform. Goal of developing cellular therapies for Huntington’s disease other neurological conditions.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 02, 2020

                          Lead Product(s) : Neural Stem Cell

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : University of California San Diego

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : First research collaboration for immunotolerance UniverCyteTM technology platform, marking launch of new business development and collaboration strategy.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 29, 2020

                          Lead Product(s) : Hypoimmunogenic Cell

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery Platform

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank